These results suggest that both systemic Inflammatory status and treatment-related immunomodulation may affect the outcome of these patients a finding that highlight a possible involvement of immunesystem in ultimate antitumor effect of this regimen, and offer a solid rationale to test our metronomic regimen in a module of sequential combination with anti-PD-1/PDL-1 inhibitors.
Pastina, P., Nardone, V., Battaglia, G., Botta, C., Tini, P., Bellan, C., et al. (2017). Immuno-Inflammatory Markers in Advanced NSCLC Patients Undergone Fractioned Cisplatin, Oral Etoposide and Bevacizumab. JOURNAL OF THORACIC ONCOLOGY, 12(Supplement 1), S921-S921 [10.1016/j.jtho.2016.11.1263].
Immuno-Inflammatory Markers in Advanced NSCLC Patients Undergone Fractioned Cisplatin, Oral Etoposide and Bevacizumab
Pierpaolo Pastina;Valerio Nardone;Battaglia Giuseppe;Cirino Botta;Paolo Tini;Cristiana Bellan;Veronica Ricci;Marcella Barbarino;Stefania Croci;Michele Caraglia;Antonio Giordano;Maria Grazia Cusi;Luigi Pirtoli;
2017-01-01
Abstract
These results suggest that both systemic Inflammatory status and treatment-related immunomodulation may affect the outcome of these patients a finding that highlight a possible involvement of immunesystem in ultimate antitumor effect of this regimen, and offer a solid rationale to test our metronomic regimen in a module of sequential combination with anti-PD-1/PDL-1 inhibitors.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Abstract .pdf
non disponibili
Tipologia:
PDF editoriale
Licenza:
PUBBLICO - Pubblico con Copyright
Dimensione
95.2 kB
Formato
Adobe PDF
|
95.2 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1056889